Literature DB >> 33849470

Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.

Marla K Johnson1, Shuyang Wu1, Daniel G Pankratz1, Grazyna Fedorowicz1, Jessica Anderson1, Jie Ding1, Mei Wong1, Manqiu Cao1, Joshua Babiarz1, Lori Lofaro1, P Sean Walsh1, Giulia C Kennedy1, Jing Huang2.   

Abstract

BACKGROUND: Bronchoscopy is a common procedure used for evaluation of suspicious lung nodules, but the low diagnostic sensitivity of bronchoscopy often results in inconclusive results and delays in treatment. Percepta Genomic Sequencing Classifier (GSC) was developed to assist with patient management in cases where bronchoscopy is inconclusive. Studies have shown that exposure to tobacco smoke alters gene expression in airway epithelial cells in a way that indicates an increased risk of developing lung cancer. Percepta GSC leverages this idea of a molecular "field of injury" from smoking and was developed using RNA sequencing data generated from lung bronchial brushings of the upper airway. A Percepta GSC score is calculated from an ensemble of machine learning algorithms utilizing clinical and genomic features and is used to refine a patient's risk stratification.
METHODS: The objective of the analysis described and reported here is to validate the analytical performance of Percepta GSC. Analytical performance studies characterized the sensitivity of Percepta GSC test results to input RNA quantity, the potentially interfering agents of blood and genomic DNA, and the reproducibility of test results within and between processing runs and between laboratories.
RESULTS: Varying the amount of input RNA into the assay across a nominal range had no significant impact on Percepta GSC classifier results. Bronchial brushing RNA contaminated with up to 10% genomic DNA by nucleic acid mass also showed no significant difference on classifier results. The addition of blood RNA, a potential contaminant in the bronchial brushing sample, caused no change to classifier results at up to 11% contamination by RNA proportion. Percepta GSC scores were reproducible between runs, within runs, and between laboratories, varying within less than 4% of the total score range (standard deviation of 0.169 for scores on 4.57 scale).
CONCLUSIONS: The analytical sensitivity, analytical specificity, and reproducibility of Percepta GSC laboratory results were successfully demonstrated under conditions of expected day to day variation in testing. Percepta GSC test results are analytically robust and suitable for routine clinical use.

Entities:  

Keywords:  Analytical validation; Bronchial brushing specimen; Genomic sequencing classifier; Lung lesion; Molecular diagnostic; Percepta

Year:  2021        PMID: 33849470     DOI: 10.1186/s12885-021-08130-x

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  9 in total

Review 1.  The British Thoracic Society guidelines on the investigation and management of pulmonary nodules.

Authors:  David R Baldwin; Matthew E J Callister
Journal:  Thorax       Date:  2015-07-01       Impact factor: 9.139

Review 2.  Smoking molecular damage in bronchial epithelium.

Authors:  Ignacio I Wistuba; Li Mao; Adi F Gazdar
Journal:  Oncogene       Date:  2002-10-21       Impact factor: 9.867

3.  A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.

Authors:  Gerard A Silvestri; Anil Vachani; Duncan Whitney; Michael Elashoff; Kate Porta Smith; J Scott Ferguson; Ed Parsons; Nandita Mitra; Jerome Brody; Marc E Lenburg; Avrum Spira
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

4.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer.

Authors:  Avrum Spira; Jennifer E Beane; Vishal Shah; Katrina Steiling; Gang Liu; Frank Schembri; Sean Gilman; Yves-Martine Dumas; Paul Calner; Paola Sebastiani; Sriram Sridhar; John Beamis; Carla Lamb; Timothy Anderson; Norman Gerry; Joseph Keane; Marc E Lenburg; Jerome S Brody
Journal:  Nat Med       Date:  2007-03-04       Impact factor: 53.440

5.  Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study.

Authors:  Hans J Lee; Peter Mazzone; David Feller-Kopman; Lonny Yarmus; Kyle Hogarth; Lori R Lofaro; Bailey Griscom; Marla Johnson; Yoonha Choi; Jing Huang; Sangeeta Bhorade; Avrum Spira; Giulia C Kennedy; Momen M Wahidi
Journal:  Chest       Date:  2020-08-03       Impact factor: 9.410

6.  Effects of cigarette smoke on the human airway epithelial cell transcriptome.

Authors:  Avrum Spira; Jennifer Beane; Vishal Shah; Gang Liu; Frank Schembri; Xuemei Yang; John Palma; Jerome S Brody
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

7.  Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  M Patricia Rivera; Atul C Mehta; Momen M Wahidi
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

  9 in total
  1 in total

1.  Clinical validation and utility of Percepta GSC for the evaluation of lung cancer.

Authors:  Peter Mazzone; Travis Dotson; Momen M Wahidi; Michael Bernstein; Hans J Lee; David Feller Kopman; Lonny Yarmus; Duncan Whitney; Christopher Stevenson; Jianghan Qu; Marla Johnson; P Sean Walsh; Jing Huang; Lori R Lofaro; Sangeeta M Bhorade; Giulia C Kennedy; Avrum Spira; M Patricia Rivera
Journal:  PLoS One       Date:  2022-07-13       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.